Compare TransMedics Group Inc (TMDX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs VNET Group Inc — how do they compare? TransMedics Group Inc trades at $87.41 (market cap $3.10B), while VNET Group Inc trades at $7.39 (market cap $2.14B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VNET | |
|---|---|---|
Market Cap | $3.10B | $2.14B |
Sector | Technology | Technology |
52-Week High | $150.42 | $14.03 |
52-Week Low | $61.99 | $6.29 |
Enterprise Value | $3.49B | $5.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
VNET trades at $7.565, up 1.14% today, with a neutral technical signal. The stock shows mixed fundamentals: revenue grew to $9.95B in 2025, but net losses deepened to -$256.77M. Recent news highlights strategic investor entry and AI-driven data center demand, yet earnings misses and a class action settlement pose concerns. Cash flow remains positive from financing, but profitability metrics like ROE at -43.21% signal challenges.
Outlook is cautious; analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio of 50.18% heighten risk. Investors should weigh growth potential from AI expansion against execution and competitive pressures in China's data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
